Dana HorÃ¡kovÃ¡

List of Publications by Year
in descending order

146 papers	6,589 citations	70961 41 h-index	74018 75 g-index
150 all docs	150 docs citations	150 times ranked	5919 citing authors

#	Article	IF	Citations
1	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 372, 1463-1472.	6.3	457
2	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
3	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	3.7	281
4	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	1.4	249
5	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurology, The, 2009, 8, 1111-1119.	4.9	233
6	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
7	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	3.7	162
8	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	2.8	158
9	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	3.6	145
10	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	2.8	143
11	Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Therapeutic Advances in Neurological Disorders, 2015, 8, 31-45.	1.5	134
12	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
13	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1573-1578.	1.2	133
14	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	1.4	126
15	Lipid profiles are associated with lesion formation over 24â€…months in interferon-Î² treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	0.9	114
16	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	4.5	100
17	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	3.7	94
18	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. American Journal of Neuroradiology, 2013, 34, 1931-1939.	1.2	90

#	Article	IF	Citations
19	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	0.9	90
20	Gray matter atrophy and disability progression in patients with early relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 112-119.	0.3	84
21	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 965-976.	1.4	77
22	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	0.9	73
23	Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. PLoS ONE, 2012, 7, e50101.	1.1	73
24	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	0.9	71
25	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Multiple Sclerosis Journal, 2016, 22, 1709-1718.	1.4	69
26	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	1.1	68
27	Alemtuzumab long-term immunologic effect. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e194.	3.1	65
28	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	0.9	63
29	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain and Behavior, 2016, 6, e00518.	1.0	58
30	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage: Clinical, 2018, 17, 444-451.	1.4	58
31	Characteristics of motor speech phenotypes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 62-69.	0.9	58
32	Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurology, 2012, 12, 10.	0.8	55
33	International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1809-1818.	1.4	55
34	Neurofilament levels are associated with bloodâ€“brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	1.4	55
35	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	1.1	54
36	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.5	54

#	Article	IF	Citations
37	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	1.4	52
38	Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T₂ Relaxometry. European Neurology, 2010, 63, 136-143.	0.6	50
39	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	0.9	49
40	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 769-779.	1.4	48
41	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. Journal of Neurology, 2014, 261, 1735-1744.	1.8	45
42	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	2.0	45
43	Serum lipid profile changes predict neurodegeneration in interferon-Î²1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	2.0	43
44	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 52-60.	1.4	41
45	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
46	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	1.5	40
47	MRI correlates of disability progression in patients with CIS over 48Âmonths. NeuroImage: Clinical, 2014, 6, 312-319.	1.4	39
48	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. Multiple Sclerosis Journal, 2017, 23, 242-252.	1.4	39
49	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 51-61.	1.4	39
50	Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. Sleep Medicine, 2012, 13, 848-851.	0.8	38
51	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.5	38
52	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. European Journal of Neurology, 2017, 24, 292-301.	1.7	38
53	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	1.4	37
54	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	1.4	37

#	Article	IF	Citations
55	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	1.4	36
56	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	1.4	36
57	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	0.9	35
58	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	0.9	35
59	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	1.4	34
60	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	0.8	33
61	Corpus Callosum Atrophy â€“ A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. European Neurology, 2012, 68, 23-27.	0.6	32
62	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	1.4	32
63	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	3.7	32
64	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
65	Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1079-1086.	1.2	29
66	A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes and Immunity, 2014, 15, 126-132.	2.2	26
67	Establishing pathological cut-offs for lateral ventricular volume expansion rates. NeuroImage: Clinical, 2018, 18, 494-501.	1.4	26
68	Cognitive clinicoâ€radiological paradox in early stages of multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 81-91.	1.7	26
69	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 475-489.	0.9	25
70	Early magnetic resonance imaging predictors of clinical progression after 48Âmonths in clinically isolated syndrome patients treated with intramuscular interferon Î²â€1a. European Journal of Neurology, 2015, 22, 1113-1123.	1.7	25
71	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1423-1437.	0.9	25
72	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335.	3.8	24

#	Article	IF	Citations
73	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	3.7	24
74	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	24
75	Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. Multiple Sclerosis and Related Disorders, 2021, 54, 103104.	0.9	23
76	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clinica Chimica Acta, 2004, 348, 147-154.	0.5	22
77	Early predictors of non-response to interferon in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 126, 390-397.	1.0	22
78	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	0.9	22
79	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	1.1	21
80	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 2016, 23, 729-736.	1.7	21
81	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. JAMA Neurology, 2020, 77, 1496.	4.5	21
82	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2020, 77, 1398.	4.5	21
83	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. Journal of Neuroimaging, 2017, 27, 620-629.	1.0	20
84	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clinical Neurology and Neurosurgery, 2012, 114, 940-946.	0.6	18
85	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes and Immunity, 2013, 14, 244-248.	2.2	18
86	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	1.4	18
87	Characterizing vocal tremor in progressive neurological diseases via automated acoustic analyses. Clinical Neurophysiology, 2020, 131, 1155-1165.	0.7	18
88	Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875918.	1.5	17
89	To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. Multiple Sclerosis and Related Disorders, 2022, 65, 104014.	0.9	17
90	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 820.	1.1	16

#	Article	IF	Citations
91	Brain volumetric correlates of dysarthria in multiple sclerosis. Brain and Language, 2019, 194, 58-64.	0.8	16
92	Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. Journal of Clinical Neuroscience, 2019, 65, 28-33.	0.8	16
93	Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3906-3919.	1.1	16
94	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	15
95	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.5	15
96	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	1.1	14
97	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	1.2	14
98	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	0.9	14
99	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. American Journal of Neuroradiology, 2015, 36, 1457-1464.	1.2	13
100	Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	13
101	Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. Multiple Sclerosis and Related Disorders, 2020, 46, 102543.	0.9	13
102	Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis. BioMed Research International, 2020, 2020, 1-6.	0.9	13
103	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	1.1	12
104	Development of gray matter atrophy in relapsingâ€“remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. Clinical Neurology and Neurosurgery, 2013, 115, S42-S48.	0.6	12
105	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.5	12
106	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
107	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 2022, 29, 1082-1090.	1.7	11
108	Patientsâ€™ Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis. European Neurology, 2009, 61, 278-284.	0.6	10

#	Article	IF	Citations
109	Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. BMC Neurology, 2017, 17, 145.	0.8	10
110	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Multiple Sclerosis International, 2013, 2013, 1-8.	0.4	9
111	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. Diagnostics, 2021, 11, 464.	1.3	9
112	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.3	9
113	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732097213.	0.5	9
114	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	1.4	9
115	Periventricular gradient of T1 tissue alterations in multiple sclerosis. NeuroImage: Clinical, 2022, 34, 103009.	1.4	9
116	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences, 2014, 347, 229-234.	0.3	8
117	Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 2017, 313, 89-91.	1.1	8
118	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	0.6	8
119	The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	0.9	8
120	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	2.7	8
121	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	1.1	8
122	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. Journal of the Neurological Sciences, 2018, 388, 87-93.	0.3	7
123	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. Multiple Sclerosis and Related Disorders, 2021, 50, 102778.	0.9	7
124	Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic. Multiple Sclerosis and Related Disorders, 2022, 59, 103391.	0.9	7
125	Pregnancyâ€induced brain magnetic resonance imaging changes in women with multiple sclerosis. European Journal of Neurology, 2022, 29, 1446-1456.	1.7	7
126	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6

#	Article	IF	Citations
127	Interpretation of Brain Volume Increase in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 401-407.	1.0	6
128	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097522.	1.5	5
129	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. Frontiers in Immunology, 2022, 13, 818325.	2.2	5
130	The Role of Highâ€Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 328-337.	1.0	4
131	The clinical and paraclinical correlates of employment status in multiple sclerosis. Neurological Sciences, 2022, 43, 1911-1920.	0.9	4
132	Validating atlas-based lesion disconnectomics in multiple sclerosis: A retrospective multi-centric study. NeuroImage: Clinical, 2021, 32, 102817.	1.4	4
133	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	1.4	3
134	Time course of lesion-induced atrophy in multiple sclerosis. Journal of Neurology, 2022, 269, 4478-4487.	1.8	3
135	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	1.7	3
136	Neuromyelitis Optica Spectrum Disorders â€“â€Š Retrospective Analysis of Clinical and Paraclinical Findings. Ceska A Slovenska Neurologie A Neurochirurgie, 2015, 78/111, 72-77.	0.0	2
137	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. Diagnostics, 2021, 11, 2230.	1.3	2
138	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	1.4	2
139	MxA <scp>mRNA</scp> decrease preceding <scp>NA</scp>b detection in <scp>IFN</scp>Î²â€treated <scp>MS</scp> patients. Brain and Behavior, 2017, 7, e00644.	1.0	1
140	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNÎ². PLoS ONE, 2017, 12, e0169957.	1.1	1
141	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	1.7	1
142	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	0.9	0
143	004â€…Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
144	Neuromyelitis optica (Devic's disease) - a rare demyelinating disease. MedicÃ¬na Pro Praxi, 2016, 13, 43-46.	0.0	0

#	Article	IF	Citations
145	098â€... Treatment escalation in secondary progressive MS identified clinically and algorithmically in relapsing remitting (RR)MS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A131.2-A131.	0.9	0
146	The influence on long-term progression of multiple sclerosis - brighter days ahead?. Neurologie Pro Praxi, 2021, 22, 40-44.	0.0	0